Tuesday, October 06, 2026

by Matt Baker, Physicians Office Resource

Breast cancer screening often begins with a brief conversation during a busy office visit. Its effectiveness, however, depends on decisions that extend well beyond ordering a mammogram: identifying elevated risk, choosing an appropriate interval, explaining breast density, and ensuring that abnormal findings reach diagnostic resolution. Primary care physicians connect these steps, often across multiple clinicians and health systems.

In 2026, that responsibility includes interpreting new guidance from the American College of Physicians (ACP) and new randomized evidence on artificial intelligence (AI) in mammography. Neither development eliminates disagreement among professional organizations. The practical challenge is to translate evolving recommendations into a documented, individualized plan that patients understand and can complete.

Screening in the 40s: A New 2026 Point of Disagreement

The US Preventive Services Task Force (USPSTF) recommendation remains biennial mammography for average-risk women aged 40 through 74. Issued in 2024, it carries a B recommendation and remains the current final guidance as of this article’s review date. The USPSTF considers both digital mammography and digital breast tomosynthesis (DBT) effective screening modalities.¹

A substantive 2026 update comes from ACP. Its April guidance recommends biennial mammography for asymptomatic, average-risk women aged 50 through 74. For those aged 40 through 49, ACP recommends discussing individual risk, benefits, and harms before deciding whether to screen. This differs from the USPSTF’s routine screening recommendation beginning at 40. ACP emphasizes false-positive findings, psychological distress, overdiagnosis, overtreatment, additional testing, and radiation exposure in its assessment.²

Other organizations continue to recommend different schedules. The American College of Radiology (ACR) recommends annual mammography beginning at 40. The American Cancer Society (ACS) offers annual screening at ages 40 through 44, recommends it at ages 45 through 54, and allows annual or biennial screening thereafter.^3,4

Physicians should explain these differences without leaving patients to choose among competing headlines. A useful discussion identifies the guideline informing the recommendation, the patient’s risk profile, and her preferences concerning earlier detection and additional testing. The conversation should end with a clear next screening date. A vague instruction to “consider mammography” can become an unintended delay.

Risk Assessment Should Precede the First Mammogram

Age-based screening is appropriate only after considering whether the patient belongs in a higher-risk pathway. ACR recommends breast cancer risk assessment by age 25, particularly emphasizing Black women and women of Ashkenazi Jewish ancestry. This is an earlier recommendation that remains relevant in 2026, rather than a newly introduced requirement.³

Risk assessment should capture family history on both maternal and paternal sides, relatives’ ages at diagnosis, known pathogenic variants, prior chest irradiation, and previous breast biopsy findings. An electronic record entry stating only “family history positive” provides little help in selecting screening or determining whether a genetics referral is warranted.

ACR recommends MRI surveillance beginning at ages 25 to 30 for several high-risk groups, including women with genetics-based risk, calculated lifetime risk of at least 20%, or chest irradiation at a young age. Mammography starting ages vary with the risk category.³ A high-risk referral should therefore produce a specific imaging schedule rather than a generic instruction to begin screening early.

Hereditary cancer assessment also has a distinct purpose. The USPSTF recommends using an appropriate brief familial risk tool when personal history, family history, or ancestry suggests BRCA-related susceptibility, followed by genetic counseling when indicated. It recommends against routine genetic risk assessment or testing when these features are absent.⁵ Estimating breast cancer risk and assessing inherited susceptibility are related tasks, but their questions and downstream decisions differ.

For office workflow, the goal is a risk assessment that can be retrieved and updated. Record the tool used, relevant inputs, resulting estimate, and clinical action. Revisit the assessment when a relative receives a new diagnosis or additional biopsy information becomes available. A previously reassuring estimate should not become a permanent designation.

Dense Breasts: Translate Notification Into a Plan

Federal breast-density notification requirements took effect September 10, 2024. They are established policy in 2026, not a new screening guideline. Mammography reports describe density, while patient summaries indicate whether breast tissue is dense and explain its implications. Heterogeneously dense and extremely dense breasts comprise the dense categories.⁶

Two messages matter clinically: dense tissue can obscure cancer on mammography, and density itself is associated with increased cancer risk. Patients need both explanations. Notification alone may generate anxiety without clarifying whether the screening plan should change.

Recommendations for additional imaging remain divided. The USPSTF finds insufficient evidence to determine the balance of benefits and harms of supplemental ultrasound or MRI following an otherwise negative mammogram in women with dense breasts. An insufficient-evidence statement does not establish that these tests are ineffective.¹

ACR recommends MRI for women with dense breasts who desire supplemental screening. In contrast, ACP’s 2026 guidance advises against supplemental screening MRI or ultrasound in asymptomatic, average-risk women with dense breasts and advises considering supplemental DBT.^2,3 These recommendations should not be extrapolated to patients with hereditary susceptibility or other high-risk indications.

The practical response is to consider density alongside the complete risk profile and consult breast imaging when the appropriate pathway is uncertain. Document the rationale for additional imaging—or for continuing mammography alone—and explain the possibility of additional recalls or biopsies. Ensure patients understand whether the proposed examination addresses a screening risk or evaluates an existing abnormality.

Choosing Imaging Without Overpromising

DBT is increasingly familiar to patients as “3D mammography.” It obtains images across the breast that allow radiologists to examine tissue in reconstructed slices. Studies suggest improved cancer detection and fewer callbacks compared with conventional 2D mammography. However, improved detection should not be equated automatically with a demonstrated reduction in breast cancer mortality.^4,7

Supplemental MRI is an important component of many high-risk pathways, but it is not a universal replacement for mammography. ACS recommends that screening MRI, when indicated, accompany mammography because either modality may detect cancers missed by the other.⁴

The order should communicate the clinical purpose. An asymptomatic patient undergoing routine screening differs from a patient with a palpable abnormality or an unresolved imaging finding. Providing symptoms, prior results, and the reason for examination helps the imaging team select an appropriate diagnostic approach. Availability matters, but a patient should not lose access to timely mammography while waiting indefinitely for a preferred technology.

New for 2026: Randomized Evidence on AI-Assisted Mammography

The Swedish Mammography Screening with Artificial Intelligence (MASAI) trial reported its interval-cancer analysis in The Lancet in January 2026. More than 105,000 women were randomized to AI-supported screening or standard double reading without AI. AI helped direct examinations to single or double radiologist reading and provided detection support.⁸

Interval cancer rates were 1.55 per 1,000 participants with AI support and 1.76 per 1,000 with standard reading. The AI strategy met the prespecified noninferiority criterion; the difference did not establish statistically significant superiority for reducing interval cancers. Sensitivity was higher with AI support—80.5% versus 73.8%—while specificity was 98.5% in both groups.⁸

These findings strengthen evidence for AI as a tool within a radiologist-led screening program. They do not demonstrate a breast cancer mortality benefit or establish that every commercial AI system performs similarly. The Swedish double-reading setting also requires consideration when applying the findings to US practice.

For referring physicians, the implication is to evaluate the quality of the imaging service, including how new technology is implemented and monitored. AI availability alone is insufficient reason to alter screening intervals, omit indicated supplemental imaging, or reassure a patient with persistent symptoms after negative screening.

Screening Is Incomplete Until Abnormal Findings Are Resolved

The Breast Imaging Reporting and Data System (BI-RADS) provides a framework for follow-up. Category 0 indicates that additional imaging evaluation is needed. Categories 1 and 2 generally return to routine screening. Category 3 commonly calls for short-interval follow-up, often at six months. Categories 4 and 5 require prompt attention to biopsy recommendations.⁷

An office should assign responsibility for tracking each unresolved result. Sending a portal message or entering an order does not establish that the next step occurred. A practical registry can record the recommended action, scheduled date, completion status, and final outcome. Escalation should address missed appointments and referrals that never generate a report.

Communication should be specific and proportionate. Explain that additional imaging does not necessarily indicate cancer, describe what the examination will clarify, and identify who will arrange it. Patients should know whom to contact if scheduling stalls. These steps can be particularly useful for patients who interpret a callback as a diagnosis and avoid further evaluation out of fear.

Screening pathways also should remain separate from symptom evaluation. A new lump or other concerning breast change warrants clinical assessment and an appropriate diagnostic pathway, even after recent negative screening. A routine future screening appointment should not substitute for evaluating a current complaint.⁷

Older Adults, Access, and the Primary Care Opportunity

Stopping screening requires attention to health status and patient goals. The USPSTF finds evidence insufficient for screening at age 75 or older. ACP’s 2026 guidance recommends discussing discontinuation at 75 or with limited life expectancy. ACS supports continued screening in women in good health with an expected survival of at least 10 years.^1,2,4

The discussion should include whether the patient would pursue diagnostic procedures and treatment if screening identified cancer. It is helpful to explain why recommendations are changing rather than simply removing mammography from the preventive-care checklist. Document the decision so another clinician does not restart or stop screening without its context.

Access deserves the same attention as modality selection. Ask about transportation, language needs, discomfort, scheduling constraints, and anticipated expense. The Women’s Preventive Services Initiative recommends individualized navigation for breast screening and follow-up, including assistance with access, referrals, education, and support services. Its screening recommendation also recognizes indicated additional imaging and pathology as steps needed to complete the screening process.⁹

Practices can translate this principle into a named contact for patients who encounter barriers. Before ordering additional testing, clarify scheduling and coverage questions with the imaging center and payer rather than promising that every examination will be covered without cost sharing. Track completion across the entire pathway, including diagnostic follow-up.

Breast cancer screening in 2026 combines established mammography recommendations, continuing disagreement about screening intensity, and emerging technology. Primary care physicians make these elements useful by assessing risk early, explaining choices clearly, and ensuring that each recommendation reaches completion. The most effective screening plan is one that fits the patient’s risk and goals—and reliably connects detection with diagnosis and care.

References

1. US Preventive Services Task Force; Nicholson WK, Silverstein M, Wong JB, et al. Screening for breast cancer: US Preventive Services Task Force recommendation statement. JAMA. 2024;331(22):1918-1930. doi:10.1001/jama.2024.5534
2. American College of Physicians. New guidance from ACP says all average-risk females aged 50-74 should undergo biennial mammography screening for breast cancer. Published April 17, 2026. Accessed October 5, 2026.
3. Monticciolo DL, Newell MS, Moy L, Lee CS, Destounis SV. Breast cancer screening for women at higher-than-average risk: updated recommendations from the ACR. J Am Coll Radiol. 2023;20(9):902-914. doi:10.1016/j.jacr.2023.04.002
4. American Cancer Society. American Cancer Society recommendations for the early detection of breast cancer. Revised July 23, 2026. Accessed October 5, 2026.
5. US Preventive Services Task Force. BRCA-related cancer: risk assessment, genetic counseling, and genetic testing. Clinical summary. Published August 20, 2019. Accessed October 5, 2026.
6. US Food and Drug Administration. Important information: final rule to amend the Mammography Quality Standards Act (MQSA). Accessed October 5, 2026.
7. National Cancer Institute. Mammograms. Updated December 2, 2025. Accessed October 5, 2026.
8. Gommers J, Hernström V, Josefsson V, et al. Interval cancer, sensitivity, and specificity comparing AI-supported mammography screening with standard double reading without AI in the MASAI study: a randomized, controlled, non-inferiority, single-blinded, population-based, screening-accuracy trial. Lancet. 2026;407(10527):505-514. doi:10.1016/S0140-6736(25)02464-X
9. Health Resources and Services Administration. Women’s preventive services guidelines. Accessed October 5, 2026.